Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

MeSH terms

• Aminobutyrates / adverse effects
• Aminobutyrates / therapeutic use*
• Angiotensin Receptor Antagonists / adverse effects
• Angiotensin Receptor Antagonists / therapeutic use*
• Biphenyl Compounds
• Drug Approval
• Drug Combinations
• Evidence-Based Medicine
• Heart Failure / diagnosis
• Heart Failure / drug therapy*
• Heart Failure / mortality
• Heart Failure / physiopathology
• Humans
• Neprilysin / antagonists & inhibitors*
• Practice Patterns, Physicians' / trends*
• Protease Inhibitors / adverse effects
• Protease Inhibitors / therapeutic use*
• Randomized Controlled Trials as Topic / methods*
• Research Design
• Risk Factors
• Tetrazoles / adverse effects
• Tetrazoles / therapeutic use*
• Treatment Outcome
• United States
• United States Food and Drug Administration
• Valsartan